高視醫療(02407.HK)香港發售股份獲小幅超額認購 預計12月12日上市
格隆匯12月9日丨高視醫療(02407.HK)發佈公吿,公司全球發售1306.86萬股股份,其中中國香港發售股份130.7萬股,國際發售股份1176.16萬股;每手買賣單位100股;摩根士丹利及海通國際為聯席保薦人;預期股份將於2022年12月12日於聯交所主板掛牌上市。
香港公開發售項下初步提呈發售的香港發售股份已獲小幅超額認購。接獲合共3124份有效申請,認購合共198.5萬股,相當於香港公開發售項下初步可供認購的發售股份約1.52倍。國際發售項下初步提呈發售的發售股份已獲小幅超額認購,相當於國際發售項下初步可供認購的發售股份約1.04倍。按發售價每股發售股份51.40港元計算,根據招股章程相關基石投資協議,基石投資者已合共認購630.44萬股發售股份。
假設超額配股權未獲行使,按發售價每股發售股份51.40港元計算,公司將收到的全球發售所得款項淨額估計約為2.831億港元。公司擬將所得款項淨額約38.2%於上市後兩年內用於提高公司的研發能力及加速其專利商業化;約29.0%將於上市後兩年內用於提高公司的產能及增強其製造能力;約9.5%將於上市後兩年內用於擴展公司的銷售及營銷;約10.6%將用作公司的營運資金及一般企業用途;及約12.7%將用於償還公司的計息借款。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.